Inclusion Criteria:  Acute non-arteritic CRAO (i.e. sudden, painless monocular vision loss) ≤ 12 hours after symptom onset confirmed by an experienced ophthalmologist through assessment of: BCVA, intraocular pressure, swinging flash light test (relative afferent pupil defect), slit-lamp biomicroscopy, fundoscopy, and OCT of the macula of both eyes* (*within the 4.5-hour time window: to be skipped if not feasible ≤ 10 minutes; beyond the 4.5-hour time window: mandatory) BCVA of LogMAR ≥ 1.3 in the affected eye (functional blindness according to WHO ICD-11) Reading must have been possible with the affected eye before CRAO (LogMAR ≤ 0.5) Neurological examination performed by an experienced stroke neurologist Brain imaging as per local standard for acute retinal ischemia/stroke assessment, either cranial computed tomography (CT) or cranial magnetic resonance imaging (MRI)  Exclusion Criteria:  Suspected giant cell arteritis Other-than-CRAO cause of acute visual loss (e.g., retinal detachment, vitreous hemorrhage, acute glaucoma, acute optic neuritis) BCVA of LogMAR < 1.3 or rapidly improving vision in the affected eye Acute ischemic stroke with indication for on-label intravenous thrombolysis (IVT) Any co-existing or terminal disease with anticipated life expectancy of < 3 months Prior participation in the REVISION trial